创始人公开信

该文件以英文原文为准，由于翻译中可能存在语意差异，中文翻译仅供参考。

今天，我们非常高兴地宣布，亿咖通科技将与 COVA Acquisition Corp. (COVA) 进行合并，并计划登陆美国资本市场。交易完成后，亿咖通科技预计将于2022年第四季度在纳斯达克交易所（Nasdaq）挂牌上市，股票代码为“ECX”。

作为设计、开发和交付智能汽车技术的全球领军企业，亿咖通科技将充分把握机遇，在汽车行业网联化、自动化和电动化浪潮中实现快速增长。此次交易所得资金，将用于加速技术研发及产品迭代，支持战略收购或投资。我们亦将依托位于英国伦敦的国际运营办公室，以及位于瑞典哥德堡的产品开发中心，在巩固欧洲市场用户的同时，进一步拓展国际市场业务。

众所周知，传统汽车时代面临终结。全球汽车行业正迈入前所未有的快速转型阶段。我们相信，汽车“基因”在未来十年经历的变革将超越过去百年。这样的变革亦将颠覆车企的开发模式，对拥有先进算力和远程软件更新能力的全新平台的需求正呼之欲出。

针对不断变化的行业需求，亿咖通科技的垂直整合的全栈汽车计算平台和底层核心技术应运而生。

自2017年成立之初，亿咖通科技就致力于通过自身技术体系赋能出行方式的变革，将传统汽车打造成为信息、通讯和交通无缝融合的智能终端。

通过不懈的技术探索和创新，这个愿景正被逐步实现。亿咖通科技也取得了切实的营收增长。目前，全球已有超过320万辆车搭载我们的产品和技术；我们也正服务全球12个OEM品牌以及8家一级汽车供应商。2021年，亿咖通科技实现了4.36亿美元的营业收入。面向未来，随着现有及目标客户群的不断扩大、先进技术路径的持续实现和国际市场的积极拓展，公司实现盈利指日可待。

创新不止，未来可期。

得益于与吉利的紧密合作，亿咖通科技在浙江吉利控股集团生态体系中的业务极具增长潜力。该生态包括吉利汽车控股有限公司（“吉利汽车”）旗下的品牌，例如吉利、几何、领克和极氪，还包括路特斯、宝腾、smart、沃尔沃汽车，以及其他与吉利控股关联或由吉利控股投资的OEM品牌。

我们，正扬帆起航。

在产品开发初期，亿咖通科技就与全球OEM客户紧密协同，共同进行趋势甄别和产品规划，尝试并探索差异化的解决方案，以持续赋能、优化车载体验。同时，亿咖通科技也充分抓住多元化的商业机会，从战略合作关系中积极寻求与第三方OEM的合作，并积极推动公司在国际市场的增长。

我们与COVA的合作将在战略和财务两个维度双管齐下，以全新的关系与模式助推下一代出行科技的加速发展。

我们期待在此项交易完成之时，再与各位分享更多激动人心的消息。

Important Additional Information Regarding the Transaction Will Be Filed With the SEC

In connection with the proposed transaction, ECARX Holdings, Inc. (“ECARX”) will file a registration statement on Form F-4 with the U.S. Securities and Exchange Commission (the “SEC”) that will include a prospectus with respect to ECARX’s securities to be issued in connection with the proposed transaction and a proxy statement with respect to the shareholder meeting of COVA Acquisition Corp. (“COVA”) to vote on the proposed transaction. Shareholders of COVA and other interested persons are encouraged to read, when available, the preliminary proxy statement/prospectus as well as other documents to be filed with the SEC because these documents will contain important information about COVA and ECARX and the proposed transaction. After the registration statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to shareholders of COVA as of a record date to be established for voting on the proposed transaction. Once available, shareholders of COVA will also be able to obtain a copy of the F-4, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: COVA Acquisition Corp., 530 Bush Street, Suite 703 San Francisco, California 94108. The preliminary and definitive proxy statement/prospectus to be included in the registration statement, once available, can also be obtained, without charge, at the SEC’s website (www.sec.gov).

Participants in the Solicitation

COVA and ECARX and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of COVA and their ownership is set forth in COVA’s filings with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of COVA’s shareholders in connection with the potential transaction will be set forth in the registration statement containing the preliminary proxy statement/prospectus when it is filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov or by directing a request to COVA Acquisition Corp., 530 Bush Street, Suite 703 San Francisco, California 94108.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on beliefs and assumptions and on information currently available to COVA and ECARX.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. These statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of COVA and ECARX, which involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or not identified in this communication, should be regarded as preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Although each of COVA and ECARX believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of COVA and ECARX caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form F-4 relating to the proposed transaction, which is expected to be filed by ECARX with the SEC and other documents filed by COVA or ECARX from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Neither COVA nor ECARX can assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including the ability to complete the business combination due to the failure to obtain approval from COVA shareholders or satisfy other closing conditions in the merger agreement, the occurrence of any event that could give rise to the termination of the merger agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption requests made by COVA public shareholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included under the heading “Risk Factors” in the registration statement on Form F-4 to be filed by ECARX with the SEC and those included under the heading “Risk Factors” in the final prospectus of COVA dated February 4, 2021 and in its subsequent filings with the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by COVA or ECARX, their respective directors, officers or employees or any other person that COVA or ECARX will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication represent the views of COVA and ECARX as of the date of this communication. Subsequent events and developments may cause those views to change. However, while COVA and ECARX may update these forward-looking statements in the future, COVA and ECARX specifically disclaim any obligation to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of COVA and ECARX as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.